omniture
logo
Search
信达生物制药（苏州）有限公司 Innovent BiologicsInc
Media Room

Photo News

rss
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

2026-06-01 08:00 5119
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

2026-06-01 08:00 5483
Innovent Announces 2025 Interim Results and Business Updates

Innovent Announces 2025 Interim Results and Business Updates

2025-08-27 18:08 4106
Innovent Biologics Showcases

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

2025-06-30 12:04 3408
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management

2025-06-27 17:49 3946
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions

Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions

2025-06-24 22:02 3532
Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation

Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation

2025-05-19 08:00 4771
Innovent Announces 2024 Annual Results and Business Updates

Innovent Announces 2024 Annual Results and Business Updates

2025-03-26 19:02 6002
Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

2025-01-17 07:00 5834
Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline

Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline

2024-06-28 08:00 4766
Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024

Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024

2024-06-25 08:00 4882
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

2024-01-02 08:00 11713
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension

Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension

2023-12-27 08:00 5672
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

2023-12-18 08:00 8470
Innovent's MSCI ESG Rating Upgraded to A

Innovent's MSCI ESG Rating Upgraded to A

2023-11-30 21:37 9104
Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

2022-06-01 08:00 4512